| Literature DB >> 30309348 |
Michela Corrò1, Joakim Skarin2, Stefan Börjesson3, Ada Rota4.
Abstract
BACKGROUND: Multi-drug methicillin-resistant Staphylococcus pseudintermedius (MRSP) detection is rapidly increasing in microbial specimens from pets across Europe. MRSP has also been isolated from bitches and newborns in dog breeding kennels. This study assessed whether MRSP lineage differs between breeding kennels and is maintained over time. Post-partum bitches (at day 3 vaginal and day 3, 9 and 35 milk samples) and their litters (at day 3, 9 and 35 oral and abdominal skin samples) from two Italian breeding kennels (A and B) were sampled and MRSP was subsequently characterized via whole-genome sequencing and antibiotic susceptibility testing. The study was carried out from October 2014 to March 2016 and included successive parturitions from the same animals.Entities:
Keywords: MRSP colonization; Postpartum bitches; Puppy; Whole-genome sequencing
Mesh:
Year: 2018 PMID: 30309348 PMCID: PMC6182839 DOI: 10.1186/s12917-018-1612-z
Source DB: PubMed Journal: BMC Vet Res ISSN: 1746-6148 Impact factor: 2.741
Chronology of isolation of MRSP in two breeding kennels (A, B), from bitches (A1,A2; B1,B2,B3,B4) samples (vagina = v; milk = m) and from mouth (o) or skin (s) samples of their puppies (p), at three sampling times (3, 9 and 35 days post-partum), in the years 2013–2014 and 2015/16. Isolates given in bold are MRSP positive. The genotyped isolates are evidenced in grey and their identification number appears beside
Breakpoints for antimicrobial susceptibility of Staphylococcus pseudintermedius or Staphylococcus spp. according to Clinical and Laboratory Standards Institute (CLSI VET 01 S3, 2015)
| Antimicrobial agent | ||||
|---|---|---|---|---|
| S | I | R | ||
| Oxacillin | ≤0.25 | – | ≥0.5 | |
| Ampicillin | ≤0.25 | – | ≥0.5 | |
| Penicillin | ≤0.5 | 1 | ≥2.0 | |
| Amoxicillin/Clavulanic acid | ≤0.25/0.12 | 0.5/0.25 | ≥1/0.5 | |
| Cefazolin | ≤2 | 4 | ≥8 | |
| Cefpodoxime | ≤2 | 4 | ≥8 | |
| Ceftiofur | ≤2 | 4 | ≥8 | |
| Trimethoprim-sulfamethox. | ≤2/38 | – | ≥4/76 | |
| Amikacin | ≤4 | 8 | ≥16 | |
| Rifampicin | ≤1 | 2 | ≥4 | |
| Enrofloxacin | ≤0.5 | 1–2 | ≥4 | |
| Marbofloxacin | ≤1 | 2 | ≥4 | |
| Clindamycin | ≤0.5 | 1–2 | ≥4 | |
| Erythromycin | ≤0.5 | 1–4 | ≥8 | |
| Doxycycline | ≤0.12 | 0.25 | ≥0.5 | |
| Chloramphenicol | ≤8 | 16 | ≥32 | |
| Gentamicina | ≤4 | 8 | ≥16 | human-derived MIC breakpoints |
| Ticarcillinb | ≤16 | 32–64 | ≥128 | human-derived MIC breakpoints |
| Ticarcillin/Clavulanic acidb | ≤16/2 | 32/2–64/2 | ≥128/2 | human-derived MIC breakpoints |
a [18] b EUCAST, [19]
Fig. 1Minimum spanning tree of the core genome MLST results from all 16 MRSP isolates (green for kennel A and yellow for kennel B) and from five Swedish isolates representing five different clusters of ST71 isolates (blue) and reference isolates from GenBank (white). The white isolates comprise strains (with NCBI accessions in parentheses): REF 1: 081661 (NZ_CP016073), REF 2: E104 (LAWU), REF 3: E140 (ANOI), REF 4: 9841787 (JTKQ), REF 5: 9841998 (JTKP), REF 6: 2001–08-299 (JTKO), REF 7: NA45 (NZ_CP016073). The results are based on analysis of 1626 genes. The numbers represent the number of allele differences between isolates, and the lines are not proportional to the number
Resistance profile of MRSP genotyped strains of kennel A (N = 11)
| DOG | A1 | A2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| YEAR | 2013 | 2014 | 2015/16 | 2014 | 2015/16 | ||||||
| b | p | p | b | p | p | p | b | b | b | p | |
| Isolate Identification N° | 9771 | 9776 | 9775 | 9778 | 9774 | 9772 | 9777 | 97710 | 9779 | 9773 | 97711 |
| MLST | ST258 | ST71 | ST71 | ST688 | ST71 | ST71 | ST71 | ST71 | ST71 | ST71 | ST71 |
| Antimicrobial agent | |||||||||||
| Oxacillin | R | R | R | R | R | R | R | R | R | R | R |
| Ampicillin | R | R | R | R | R | R | R | R | R | R | R |
| Penicillin | R | R | R | R | R | R | R | R | R | R | R |
| Ticarcillin | S | R | R | R | R | R | R | R | R | R | R |
| Ticarcillin/Clavulanic acid | S | R | R | R | R | R | R | R | R | R | R |
| Amoxicillin/Clavulanic acid | S | R | R | R | R | R | R | R | R | R | R |
| Cefazolin | S | R | R | R | R | R | R | R | R | R | R |
| Cefpodoxime | R | R | R | R | R | R | R | R | R | R | R |
| Ceftiofur | R | R | R | R | R | R | R | R | R | R | R |
| Trimethoprim-sulfamethox. | R | R | R | R | R | R | R | R | R | R | R |
| Gentamicin | S | R | R | S | R | R | R | R | R | R | R |
| Amikacin | S | S | I | S | I | I | S | I | R | I | I |
| Rifampicin | S | S | S | S | S | S | S | S | S | S | S |
| Enrofloxacin | S | R | R | R | R | R | R | R | R | R | R |
| Marbofloxacin | S | R | R | R | R | R | R | R | R | R | R |
| Clindamycin | R | R | R | R | R | R | R | R | R | R | R |
| Erythromycin | R | R | R | R | R | R | R | R | R | R | R |
| Doxycycline | R | R | R | R | R | R | R | R | R | R | S |
| Chloramphenicol | I | I | I | R | I | I | I | I | I | I | I |
b bitch, p puppy, S susceptible, I intermediate, R resistant
Resistance profile of MRSP genotyped strains of kennel B (N = 5)
| DOG | B1 | B2 | |||
|---|---|---|---|---|---|
| p | b | b | p | b | |
| Isolate Identification N° | 58–2016 | 161–2014 | 730–2016 | 730–2014 | 938–2014 |
| MLST | ST772 | ST772 | ST772 | ST772 | ST772 |
| Antimicrobial agent | |||||
| Oxacillin | R | R | R | R | R |
| Ampicillin | R | R | R | R | R |
| Penicillin | R | R | R | R | R |
| Ticarcillin | I | S | S | R | I |
| Ticarcillin/Clavulanic acid | S | S | S | R | R |
| Amoxicillin/Clavulanic acid | S | R | R | R | R |
| Cefazolin | R | R | R | R | R |
| Cefpodoxime | R | R | R | R | R |
| Ceftiofur | R | R | R | R | R |
| Trimethoprim-sulfamethox. | R | R | R | R | R |
| Gentamicin | R | R | R | R | R |
| Amikacin | R | R | R | R | R |
| Rifampicin | R | S | S | R | R |
| Enrofloxacin | S | S | S | R | R |
| Marbofloxacin | S | S | S | R | R |
| Clindamycin | R | R | R | R | R |
| Erythromycin | R | R | R | R | R |
| Doxycycline | R | S | R | R | R |
| hloramphenicol | R | I | R | R | R |
b bitch, p puppy, S susceptible, I intermediate, R resistant